[ad_1]
Sharjah 24 / AFP:
The Swiss pharmaceutical group Roche has announced that it has completed two clinical trials on Alzheimer's disease as part of the latest research on the disease.
The Basel-based group said in a statement that it has completed two phase III studies, Creed 1 and Creed 2, on the Krinizumab molecule developed with the Swiss biotechnology laboratory AC Immunology. Early appearance of the disease.
Roche explained that the badysis conducted by an independent committee concluded that it was unlikely that these studies would achieve the stated objectives.
"These findings contribute significantly to our understanding of Alzheimer's disease," said Sandra Hornning, MD, responsible for new product development.
The molecule is still being researched as part of another program in Colombia aimed at healthy people whose family is at risk of contracting the disease, while other treatments come under Roche.
Dementia affects about 50 million people worldwide, with about 10 million new cases diagnosed each year, while Alzheimer's disease is one of the most common forms of these diseases, according to the group Swiss.
There is no cure for this disease because the drugs used only relieve symptoms without stopping the progression of Alzheimer's disease.
Source link
